Treatment of modified stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach

S. B. Newman, T. R. DeMeester, H. M. Golomb, P. C. Hoffman, A. G. Little, V. Raghavan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Twenty patients with postsurgical, modified Stage II (T2 N1 M0, T1 N1 M0) non-small cell bronchogenic carcinoma were seen between 1974 and 1981 and were evaluated in a retrospective manner. Fifteen patients had T2 N1 M0 lesions, while 5 patients had T1 N1 M0 disease. Eight patients were treated with surgical resection alone, of whom seven had died, with a median survival of 12.0 months. Four patients received surgical resection and postoperative radiation therapy, of whom two had died, with a median survival not reached at 37 months. Eight patients were treated with surgical resection, radiation therapy, and adjuvant chemotherapy including cyclophosphamide (C), doxorubicin (A), methotrexate (M), and procarbazine (P). Six patients are alive and free of disease, with a median survival not yet reached at 72 months. There is a significant survival advantage for the 12 patients treated with combined modality therapy (surgical resection + radiation therapy; surgical resection + radiation therapy + chemotherapy) compared to the eight patients treated with SR alone (p < 0.01), and for the eight patients receiving chemotherapy versus the 12 patients who did not (p < 0.01). In spite of thorough clinical and surgical staging, patients with T1 and T2 primary tumors with N1 disease have a high relapse rate, predominantly in metastatic sites. Adjuvant radiation therapy and chemotherapy appear to benefit these patients with modified Stage II non-small cell bronchogenic carcinoma.

Original languageEnglish
Pages (from-to)180-185
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume86
Issue number2
StatePublished - Sep 29 1983
Externally publishedYes

Fingerprint

Bronchogenic Carcinoma
Radiotherapy
Therapeutics
Survival
Drug Therapy
Procarbazine
Combined Modality Therapy
Adjuvant Chemotherapy
Methotrexate
Doxorubicin
Cyclophosphamide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Newman, S. B., DeMeester, T. R., Golomb, H. M., Hoffman, P. C., Little, A. G., & Raghavan, V. (1983). Treatment of modified stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach. Journal of Thoracic and Cardiovascular Surgery, 86(2), 180-185.

Treatment of modified stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach. / Newman, S. B.; DeMeester, T. R.; Golomb, H. M.; Hoffman, P. C.; Little, A. G.; Raghavan, V.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 86, No. 2, 29.09.1983, p. 180-185.

Research output: Contribution to journalArticle

Newman, SB, DeMeester, TR, Golomb, HM, Hoffman, PC, Little, AG & Raghavan, V 1983, 'Treatment of modified stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach', Journal of Thoracic and Cardiovascular Surgery, vol. 86, no. 2, pp. 180-185.
Newman, S. B. ; DeMeester, T. R. ; Golomb, H. M. ; Hoffman, P. C. ; Little, A. G. ; Raghavan, V. / Treatment of modified stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach. In: Journal of Thoracic and Cardiovascular Surgery. 1983 ; Vol. 86, No. 2. pp. 180-185.
@article{4d83d7d7054d4b558c4ed4b8b789176f,
title = "Treatment of modified stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach",
abstract = "Twenty patients with postsurgical, modified Stage II (T2 N1 M0, T1 N1 M0) non-small cell bronchogenic carcinoma were seen between 1974 and 1981 and were evaluated in a retrospective manner. Fifteen patients had T2 N1 M0 lesions, while 5 patients had T1 N1 M0 disease. Eight patients were treated with surgical resection alone, of whom seven had died, with a median survival of 12.0 months. Four patients received surgical resection and postoperative radiation therapy, of whom two had died, with a median survival not reached at 37 months. Eight patients were treated with surgical resection, radiation therapy, and adjuvant chemotherapy including cyclophosphamide (C), doxorubicin (A), methotrexate (M), and procarbazine (P). Six patients are alive and free of disease, with a median survival not yet reached at 72 months. There is a significant survival advantage for the 12 patients treated with combined modality therapy (surgical resection + radiation therapy; surgical resection + radiation therapy + chemotherapy) compared to the eight patients treated with SR alone (p < 0.01), and for the eight patients receiving chemotherapy versus the 12 patients who did not (p < 0.01). In spite of thorough clinical and surgical staging, patients with T1 and T2 primary tumors with N1 disease have a high relapse rate, predominantly in metastatic sites. Adjuvant radiation therapy and chemotherapy appear to benefit these patients with modified Stage II non-small cell bronchogenic carcinoma.",
author = "Newman, {S. B.} and DeMeester, {T. R.} and Golomb, {H. M.} and Hoffman, {P. C.} and Little, {A. G.} and V. Raghavan",
year = "1983",
month = "9",
day = "29",
language = "English",
volume = "86",
pages = "180--185",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of modified stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach

AU - Newman, S. B.

AU - DeMeester, T. R.

AU - Golomb, H. M.

AU - Hoffman, P. C.

AU - Little, A. G.

AU - Raghavan, V.

PY - 1983/9/29

Y1 - 1983/9/29

N2 - Twenty patients with postsurgical, modified Stage II (T2 N1 M0, T1 N1 M0) non-small cell bronchogenic carcinoma were seen between 1974 and 1981 and were evaluated in a retrospective manner. Fifteen patients had T2 N1 M0 lesions, while 5 patients had T1 N1 M0 disease. Eight patients were treated with surgical resection alone, of whom seven had died, with a median survival of 12.0 months. Four patients received surgical resection and postoperative radiation therapy, of whom two had died, with a median survival not reached at 37 months. Eight patients were treated with surgical resection, radiation therapy, and adjuvant chemotherapy including cyclophosphamide (C), doxorubicin (A), methotrexate (M), and procarbazine (P). Six patients are alive and free of disease, with a median survival not yet reached at 72 months. There is a significant survival advantage for the 12 patients treated with combined modality therapy (surgical resection + radiation therapy; surgical resection + radiation therapy + chemotherapy) compared to the eight patients treated with SR alone (p < 0.01), and for the eight patients receiving chemotherapy versus the 12 patients who did not (p < 0.01). In spite of thorough clinical and surgical staging, patients with T1 and T2 primary tumors with N1 disease have a high relapse rate, predominantly in metastatic sites. Adjuvant radiation therapy and chemotherapy appear to benefit these patients with modified Stage II non-small cell bronchogenic carcinoma.

AB - Twenty patients with postsurgical, modified Stage II (T2 N1 M0, T1 N1 M0) non-small cell bronchogenic carcinoma were seen between 1974 and 1981 and were evaluated in a retrospective manner. Fifteen patients had T2 N1 M0 lesions, while 5 patients had T1 N1 M0 disease. Eight patients were treated with surgical resection alone, of whom seven had died, with a median survival of 12.0 months. Four patients received surgical resection and postoperative radiation therapy, of whom two had died, with a median survival not reached at 37 months. Eight patients were treated with surgical resection, radiation therapy, and adjuvant chemotherapy including cyclophosphamide (C), doxorubicin (A), methotrexate (M), and procarbazine (P). Six patients are alive and free of disease, with a median survival not yet reached at 72 months. There is a significant survival advantage for the 12 patients treated with combined modality therapy (surgical resection + radiation therapy; surgical resection + radiation therapy + chemotherapy) compared to the eight patients treated with SR alone (p < 0.01), and for the eight patients receiving chemotherapy versus the 12 patients who did not (p < 0.01). In spite of thorough clinical and surgical staging, patients with T1 and T2 primary tumors with N1 disease have a high relapse rate, predominantly in metastatic sites. Adjuvant radiation therapy and chemotherapy appear to benefit these patients with modified Stage II non-small cell bronchogenic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020616871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020616871&partnerID=8YFLogxK

M3 - Article

C2 - 6308356

AN - SCOPUS:0020616871

VL - 86

SP - 180

EP - 185

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 2

ER -